clinical trial bpc-157 humans Peptide Pentadecapeptide BPC 157, in Clinical
Description
Knockdown of NNMT in adipocytes was associated with increased NAD+ levels and altered expression of genes involved in energy expenditure, providing the rationale for pharmacological NNMT inhibition [2]
10.1038/srep32893 Sci
doi: 10.5217/ir.2015.13.1.11
In-vitro studies
